Jump to content

Solengepras

Add links
From Wikipedia, the free encyclopedia

Solengepras
Clinical data
Other namesSolangepras (former proposed INN); CVN-424; CVN424
Routes of
administration		Oral[1]
Drug classGPR6 inverse agonist
Identifiers
  • 1-[2-[4-(2,4-difluorophenoxy)piperidin-1-yl]-3-[[(3R)-oxolan-3-yl]amino]-7,8-dihydro-5H-pyrido[3,4-b]pyrazin-6-yl]ethanone
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC24H29F2N5O3
Molar mass473.525 g·mol−1
3D model (JSmol)
  • CC(=O)N1CCC2=C(C1)N=C(C(=N2)N3CCC(CC3)OC4=C(C=C(C=C4)F)F)N[C@@H]5CCOC5
  • InChI=1S/C24H29F2N5O3/c1-15(32)31-10-6-20-21(13-31)28-23(27-17-7-11-33-14-17)24(29-20)30-8-4-18(5-9-30)34-22-3-2-16(25)12-19(22)26/h2-3,12,17-18H,4-11,13-14H2,1H3,(H,27,28)/t17-/m1/s1
  • Key:HSWVJQBEXRKOBZ-QGZVFWFLSA-N

Solengepras (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, developmental code name CVN-424), is an inverse agonist of the orphan G protein-coupled receptor 6 (GPR6) which is under development for the treatment of Parkinson's disease.[1][2][3][4][5] It is a small molecule and is taken orally.[1][5] Solengepras produces hyperlocomotion and reverses haloperidol-induced catalepsy in rodents.[5] It is being developed by Cerevance.[1][2] As of March 2026, solengepras is in phase 3 clinical trials for Parkinson's disease.[1][2] Positive results of phase 3 trials were released in October 2026.[6][7][8][9]

The drug was initially assigned the proposed INN solangepras in 2025.[10] The name was subsequently corrected to solengepras,[11] which was established as the recommended INN in September 2026.[12]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 "Solengepras". AdisInsight. 21 October 2024. Retrieved 25 February 2025.
  2. 1 2 3 "Delving into the Latest Updates on CVN-424 with Synapse". Synapse. 5 February 2025. Retrieved 25 February 2025.
  3. ↑ Tian X, Ali S, Allen JA, Zhou J (April 2026). "CVN-424: An Advanced GPR6 Inverse Agonist in Phase III Clinical Trials for Parkinson's Disease". J Med Chem. 69 (7): 7507–7511. doi:10.1021/acs.jmedchem.6c00866. PMC 13105250. PMID 41952522.
  4. ↑ Gros P, Garcia LA, Fox SH (2025). "Experimental Therapeutics in Parkinson's Disease". Neurologic Clinics. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID 40185528.
  5. 1 2 3 Brice NL, Schiffer HH, Monenschein H, Mulligan VJ, Page K, Powell J, et al. (June 2021). "Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease". The Journal of Pharmacology and Experimental Therapeutics. 377 (3): 407–416. doi:10.1124/jpet.120.000438. PMID 33795395.
  6. ↑ Dalton J (7 October 2026). "New pill for Parkinson's disease offers hope of treating symptoms and with fewer side-effects". The Independent. Retrieved 9 October 2026.
  7. ↑ Russo M (7 October 2026). "Cerevance rescues its Parkinson's drug with phase 3 win". Fierce Biotech. Retrieved 9 October 2026.
  8. ↑ Bell J (7 October 2026). "A Takeda spinout builds case for its Parkinson's drug". BioPharma Dive. Retrieved 9 October 2026.
  9. ↑ Blakely R (7 October 2026). "Daily pill heralds new era in Parkinson's treatment". The Times. Retrieved 9 October 2026.
  10. ↑ "INN Proposed List 133". World Health Organization. 10 July 2025. Retrieved 27 October 2026.
  11. ↑ "INN Proposed List 134". World Health Organization. 29 January 2026. Retrieved 27 October 2026.
  12. ↑ "INN Recommended List 96". World Health Organization. 29 September 2026. Retrieved 27 October 2026.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=Solengepras&oldid=1383471971"